+2,080.8%
AMD vs MRNA
+786.4%
+1,294.5%
-65.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -13.2% | -2.2% | -11.1% | -13.0% |
| 7D | -20.5% | -12.7% | -7.8% | -19.5% |
| 30D | -23.2% | -20.7% | -2.5% | -21.5% |
| 3M | -9.6% | +46.3% | -55.9% | -12.9% |
| 6M | -5.2% | +305.2% | -310.4% | -26.1% |
| YTD | +98.2% | +561.2% | -463.1% | +41.5% |
| 1Y | +106.0% | +772.1% | -666.1% | +40.2% |
| 3Y | +249.2% | +147.0% | +102.2% | +175.4% |
| 5Y | +173.1% | -26.1% | +199.2% | +144.6% |
| All | +2,080.8% | +786.4% | +1,294.5% | +1,171.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling